Brisbane, June 23, 2016 - (ABN Newswire) - Anatara Lifesciences (ASX:ANR) is pleased to release a copy of the presentation that Chairman, Dr Mel Bridges presented at the Finance News Network CEO Conference and the Gold Coast Investment Showcase this week.
Presentation Highlights Include:
- Data on the growing need for a safe and effective alternative to the use of antibiotics in the production of livestock animals and in humans
- An outline of the clear path to market for Anatara’s lead compound, Detach(TM) - a safe, naturally derived alternative to the use of antibiotics to control diarrhoea, with Australian market launch for Detach(TM) in pigs planned for 2017
- A summary of the exclusive option to licence Detach(TM) for worldwide commercialisation with leading animal health company, Zoetis, and
- More information on the recently announced research and development collaboration with The La Trobe Institute for Molecular Science, aimed at developing active components within Detach(TM) for the treatment of inflammatory diseases in humans and in companion animals
The Anatara team plans a further market update and extensive investor roadshow in July.
To view the presentation, please visit: http://abnnewswire.net/lnk/DE4473SS
About: Anatara Lifesciences Ltd
Anatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(TM) is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called “super bugs” that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.
